Related Experiment Videos
Thalidomide in cutaneous lupus erythematosus.
Michelle T Pelle1, Victoria P Werth
1Department of Dermatology, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
American Journal of Clinical Dermatology
|May 24, 2003
Summary
Thalidomide, despite past controversies, shows significant efficacy in treating cutaneous lupus erythematosus. Careful monitoring and controlled access are crucial for its safe use in refractory cases.
Area of Science:
- Immunology
- Dermatology
- Pharmacology
Background:
- Thalidomide, initially known for teratogenicity, has evolved into a therapeutic agent for leprosy and erythema nodosum leprosum.
- Its anti-inflammatory and immunosuppressant properties, including cytokine modulation, are now recognized.
- Cutaneous lupus erythematosus (CLE) is a target for thalidomide therapy.
Purpose of the Study:
- To evaluate the efficacy and safety of thalidomide in treating cutaneous lupus erythematosus.
- To review the drug's historical context and evolving therapeutic applications.
- To highlight the importance of risk management strategies for thalidomide use.
Main Methods:
- Review of clinical data and case series on thalidomide for CLE.
- Analysis of therapeutic outcomes, including amelioration and remission rates.
- Assessment of adverse effects and necessary prescribing controls.
Main Results:
- Thalidomide ameliorated CLE in approximately 90% of patients reviewed.
- Remission rates ranged from 15-20% at daily doses of 50-400 mg.
- Neuropathic effects and contraceptive concerns are noted limitations.
Conclusions:
- Thalidomide is an effective treatment option for refractory cutaneous lupus erythematosus.
- Strict physician monitoring and controlled drug access are essential for safe prescription.
- Risk management strategies mitigate the known adverse effects of thalidomide.